Campath-1H monoclonal antibody therapy

Current Opinion in Oncology

Volumn 12, Issue 6, 2000, Pages 574-581

  Flynn, Joseph M ^a   Byrd, John C ^a,b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CD52 ANTIGEN; MONOCLONAL ANTIBODY; RITUXIMAB; TRASTUZUMAB;

ALLOGRAFT; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; APOPTOSIS; AUTOIMMUNITY; BLOOD DISEASE; BONE MARROW CELL; DRUG EFFICACY; GENETIC ENGINEERING; HUMAN; METABOLIC ACTIVATION; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; CLINICAL TRIALS; HEMATOLOGIC NEOPLASMS; HUMANS; MICE;

EID: 0034501632     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200011000-00010     Document Type: Review

References (75)

1. Monoclonal antibody therapy in cancer
2. Reshaping human antibodies for therapy
3. Emergence of CD52-, glycosylphosphatidylinositol-anchor-deficient lymphocytes in rheumatoid arthritis patients following Campath-1 H treatment
4. Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection
5. Persistence of CD4+ T cells in the arthritic joint after CAMPATH-1H treatment
6. Humanised monoclonal antibody therapy for rheumatoid arthritis
7. CAMPATH-1H in rheumatoid arthritis: An intravenous dose-ranging study
8. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis
9. CAMPATH-IH in multiple sclerosis
10. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis
11. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis
12. Campath-1H therapy in refractory ocular inflammatory disease
13. Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H
14. T cell depletion with Campath-1 in allogeneic bone marrow transplantation
15. CAMPATH-1 monoclonal antibodies in bone marrow transplantation
16. Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection
17. In vivo use of Campeth-1G to prevent graft-versus-host disease and graft rejection after bone marrow transplantation
18. T cell depletion by exposure to Campath-1G in vitro prevents graft-versus-host disease
19. "Almost tolerance" in the clinic
20. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients
21. Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients
22. Clearance of PCR-detectable lymphoma cells from the peripheral blood, but not bone marrow after therapy with campath-1H
23. Remission induction in non-Hodgkin lymphome with reshaped human monoclonal antibody CAMPATH-1H
24. Clonel CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52)
25. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: A phase II multicenter study
26. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody
27. Levels of expression of CD52 in normal and leukemic B and T cells: Correlation with in vivo therapeutic responses to Campath-1H
28. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia
29. Phese II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia
30. Campath-1H therapy in 29 patients with refractory CLL: "true" complete remission is en attainable goal
31. Campath-1H in B-chronic lymphocytic leukemia: Report on a patient treated thrice in a 3 year period
32. Campath1H therapy for patients with refractory chronic lymphocytic leukemia (CLL)
33. Control of hyperlymphocytosis and splenomegaly with Campath-1H in advanced refractory B-cell chronic lymphocytic leukemia (B-CLL)
34. Effects of Campath-1 antibodies in vivo in patients wth lymphoid malignancies: Influence of antibody isotype
35. Blocking with sandoglobulin (total human IgG) improves the biodistribution of the radiolabelled monoclonal antibody (MAB) Campath-1H
36. The CAMPATH-1 antigen (CDw52)
37. Characterization of the CAMPATH-1 (CDw52) antigen: Biochemical analysis and cDNA cloning reveal an unusually small peptide backbone
38. 1.9 A structure of the therapeutic antibody CAMPATH-1H lab in complex with a synthetic peptide antigen
39. Primary structure of CD52
40. High-performance liquid chromatographic mapping of the oligosaccharides released from the humanised immunoglobulin, CAMPATH 1H
41. Mass spectrometry of the humanized monoclonal antibody CAMPATH 1H
42. Recognition of CD52 allelic gene products by CAMPATH-1H antibodies
43. The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H
44. Engineering multiple-domain forms of the therapeutic antibody CAMPATH- 1H: Effects on complement lysis
45. Improved biodistribution, tumor targeting, and reduced immunogenicity in mice with a gamma 4 variant of Campath-1H
46. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells
47. Campath-1H induces apoptosis in human chronic lymphocytic leukemia cells (CLL) in vitro independent of complement mediated lysis of Fcg receptor ligation
48. Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes
49. Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H
50. Subcutaneous administration of CAMPATH-1H: Clinical and biological outcomes
51. Immunosuppressive toxicity of CAMPATH1H monoclonal antibody in the treatment of patients with recurrent low grade lymphoma
52. Sézary cell leukaemia: A distinct T cell disorder or a variant form of T prolymphocytic leukaemia?
53. The Campath-1 antigen (CDw52)
54. A randomized comparison of fludarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia: A CALGB, SWOG, CTG/NCT-c, and ECOG intergroup study
55. Multicenter study of Campath-1H in patients with chronic lymphocytic Leukemia (B-CLL) refractory to fludarabine
56. Campath-1H in the treatment of T-prolymphocytic leukemia (T-PLL)
57. Differential response in a patient treated with Campath-1H monoclonal antibody for refractory non-Hodgkin lymphoma
58. Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas
59. Elimination of graft versus host disease by in vitro depletion of alloreactive lymphocytes using a monoclonal rat antihuman lymphocyte antibody (Campath-1)
60. Comparative analysis of in vivo T cell depletion with radiotherapy, combination chemotherapy, and the monoclonal antibody Campath-1G, using limiting dilution methodology
61. T-cell-depleted allogeneic bone marrow transplantation acute leukemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse
62. Reactivity of rat monoclonal antibody Campath-1 with human leukaemia cells and its possible application for autologous bone marrow transplant
63. Cytokine-release syndrome in patients with B-cell chronic Tymphocytic leukemia and high lymphocyte counts after treatment with anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)
64. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: Involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells
65. Treatment of Lymphoid malignancies with Campath-1H is associated with elevated serum levels of IL-6 and TNF alpha
66. CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis: An intravenous dose-escalation study
67. Adverse reactions to Campath-1H monoclonal antibody
68. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL): Implications for clinical trials in this patient population
69. In vivo "purging" of residual disease in CLL with Campath-1H
70. Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia
71. The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment
72. Phase II clinical trial of Campath-1H in refractory hematologic malignancies expressing the surface antigen CD52
73. Immunosuppression and opportunistic infections (OI) in patients with chronic lymphocytic Leukemia (CLL) following Campath-1H therapy
74. Campath-1H: A monoclonal antibody for treatment of non-Hodgkin's and chronic lymphatic leukemia